413599-62-9
| 中文名称 | 413599-62-9 |
|---|---|
| 中文同义词 | 化合物ZD-4190 |
| 英文名称 | ZD-4190 |
| 英文同义词 | ZD-4190;ZD-4190;ZD 4190;ZD4190;4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-;Inhibitor,inhibit,Vascular endothelial growth factor receptor,VEGFR,Epidermal growth factor receptor,EGFR,ZD 4190,ErbB-1,HER1,ZD-4190,ZD4190 |
| CAS号 | 413599-62-9 |
| 分子式 | C19H16BrFN6O2 |
| 分子量 | 459.27 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 413599-62-9.mol |
| 结构式 |  |
413599-62-9 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | DMSO：20.83 mg/mL (45.35 mM)；水：< 0.1 mg/mL（不溶） |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| Target | Value |
|
KDR
() | |
|
Flt-1
() |
ZD4190 exhibits cytotoxic activity against the tumor cells.
ZD4190 (100 mg/kg, p.o.) effectively delays MDA-MB-435 tumor growth in mice. In ZD4190-treated tumors, 18F-FPPRGD2 uptake has decreased significantly relative to baseline by 26.74±8.12% (p<0.05) on day 1 and by 41.19±6.63% (p<0.01) on day 3, then has returned to baseline on day 7. Tumor uptake of 18F-FLT has also decreased on both day 1 and day 3 after initiation of ZD4190 treatment. However, ZD4190 does not significantly change 18F-FDG uptake in tumors, compared with the control group. ZD4190 (50 mg/kg, p.o.) prevents outgrowth of residual tumour in a muscle model of minimal residual carcinoma. ZD4190 (12.5-100 mg/kg, p.o.) produces a dose-dependent reduction in K(trans) in PC-3 prostate tumors. At 100 mg/kg, ZD4190 reduces K(trans) in PC-3 tumors by 31% following 2 doses and by 53% following 8 doses.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-U00002 | ZD-4190 | 1 mg | 850元 | |
| 2024/04/30 | HY-U00002 | 413599-62-9 ZD-4190 | 413599-62-9 | 5mg | 2200元 |